Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc (APTO) is a clinical-stage biotechnology company pioneering precision therapies for hematologic malignancies. This page serves as the definitive source for verified news and scientific updates related to APTO's innovative oncology pipeline.
Key resources include: Press releases on clinical trial progress, regulatory milestones, partnership announcements with pharmaceutical collaborators, and analyses of treatment mechanisms. Investors will find essential updates on the company's small molecule inhibitors and combination therapy developments targeting AML and high-risk MDS.
Our news collection enables: Tracking of APTO's progress in genetic-guided therapies, monitoring of FDA interactions, and insights into strategic collaborations advancing personalized cancer treatments. Content is curated to meet investor and researcher needs without promotional bias.
Bookmark this page for real-time updates on APTO's scientific advancements and corporate developments. Always consult official filings for investment decisions.
Aptose Biosciences Inc. (Nasdaq: APTO) will report its financial results for the quarter ended September 30, 2021, and provide a corporate update on November 11, 2021. The company is focused on developing personalized cancer therapies, particularly in hematology. Key investigational products include luxeptinib, a first-in-class kinase inhibitor for B cell malignancies and acute myeloid leukemia, and APTO-253, which targets the MYC oncogene. The conference call will occur at 5:00 PM ET, accessible via a toll-free number or online webcast.
Aptose Biosciences has appointed Janet Clennett as Vice President of Finance and Roger Davies as Vice President of Operations. Clennett, a CPA with over 15 years of experience in finance at biotech firms, has been with Aptose since 2017. Davies brings 25 years of senior project management experience, particularly in oncology. These additions aim to strengthen Aptose's financial and operational capabilities as the company pursues growth and clinical expansion in its oncology pipeline, which includes investigational products for hematologic malignancies.
Aptose Biosciences, a clinical-stage biotech firm (Nasdaq: APTO), is set to present at two upcoming virtual conferences in September 2021. The first, the H.C. Wainwright 23rd Annual Global Investment Conference, will take place on September 13 starting at 7:00 AM EDT, with a dedicated webcast. The second, the Cantor Global Healthcare Conference, is on September 28 at 11:20 AM EDT, also featuring a webcast. These events showcase Aptose's commitment to developing cancer therapies.
Aptose Biosciences reported a net loss of $13.5 million for Q2 2021, down from $15.8 million in Q2 2020. For the six-month period, the net loss rose to $29.7 million compared to $27.3 million in 2020. Total cash and equivalents stood at $103.3 million, sufficient to fund operations into H1 2023. Key highlights include full enrollment in the Luxeptinib Phase 1a/b studies for AML and B-cell malignancies, and continued dose escalation for APTO-253 in AML/MDS. The announcement was made on August 3, 2021, ahead of a conference call scheduled for the same day.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will release its financial results for Q2 2021 on August 3, 2021, after market close. The company is focused on developing innovative cancer therapies, with two clinical-stage products targeting hematologic malignancies: luxeptinib and APTO-253. A conference call to discuss the results will be held on the same day at 5:00 PM ET, accessible via phone or webcast. Financial statements will be available on SEDAR and EDGAR.
Aptose Biosciences presented an update on its oncology pipeline on June 11, 2021, during the EHA2021 Virtual Congress. The focus was on luxeptinib, an oral FLT3 and BTK inhibitor undergoing Phase 1a/b trials for relapsed acute myeloid leukemia (AML) and B-cell malignancies. Positive results include durable MRD-negative complete response in AML and anti-tumor activity in B-cell malignancies. The company is also developing APTO-253, a MYC inhibitor, which is in Phase 1a/b trials for AML and high-risk myelodysplastic syndrome (MDS). Future updates are expected as trials progress.
Aptose Biosciences announced the results of its annual meeting held on June 1, 2021, where 72.83% of shareholders participated. All board nominees were elected, with Carol G. Ashe receiving 99.25% of votes for her position. Key resolutions passed included the reappointment of KPMG LLP as auditors, approval of the 2021 Stock Incentive Plan, and the 2021 Employee Stock Purchase Plan. Additionally, shareholders supported a non-binding resolution for executive compensation. Details on these results are available on SEDAR and EDGAR.
Aptose Biosciences (NASDAQ: APTO) announced a corporate update scheduled for June 11, 2021, at 8:00 AM ET during the EHA2021 Virtual Congress. The update will highlight clinical data for two investigational products: luxeptinib (CG-806), a FLT3 and BTK kinase inhibitor in trials for relapsed or refractory acute myeloid leukemia (AML) and B-cell malignancies, and APTO-253, a MYC repressor for patients with relapsed AML or high-risk myelodysplastic syndromes (MDS). Early clinical data will also be presented in posters on June 11, 2021.
Aptose Biosciences, a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The RBC Capital Markets Global Healthcare Virtual Conference is set for May 19, 2021, from 11:30 AM to 11:55 AM EDT, featuring a fireside chat with Gregory J. Renza, M.D. The Jefferies Virtual Healthcare Conference follows on June 2, 2021, at 2:00 PM EDT, where Aptose will present a slide deck and host a webcast. The company focuses on developing innovative cancer therapeutics, including luxeptinib and APTO-253, aimed at treating various hematological malignancies.
Aptose Biosciences (NASDAQ: APTO) reported a net loss of $16.2 million for Q1 2021, up from $11.5 million in Q1 2020. Research and development expenses rose to $8.2 million, driven by increased costs for luxeptinib and APTO-253 trials. The company continues dose escalations in its Phase 1 a/b studies for luxeptinib in AML and B-cell malignancies. Dr. Jotin Marango has been appointed as Chief Financial Officer. Aptose maintains a solid cash position of $112.1 million, expected to support operations into 2023. Updates on clinical trials are anticipated at the upcoming EHA Virtual Congress in June.
